| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2025/03/07 | 21 : 08 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/03/07 | 21 : 07 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/02/19 | 07 : 25 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/02/07 | 08 : 30 | Edgar (US Regulatory) | Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/02/05 | 06 : 58 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/02/05 | 06 : 58 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/01/23 | 22 : 13 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/01/23 | 22 : 12 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/01/23 | 22 : 00 | Business Wire | NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/01/23 | 06 : 27 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/01/11 | 08 : 06 | Edgar (US Regulatory) | Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2025/01/10 | 21 : 03 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/12/19 | 21 : 00 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/12/19 | 20 : 50 | Business Wire | NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/12/12 | 06 : 12 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/12/09 | 21 : 05 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/12/09 | 20 : 50 | Business Wire | NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/27 | 06 : 08 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/23 | 06 : 27 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/23 | 06 : 05 | Business Wire | NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024 | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/15 | 22 : 10 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/15 | 22 : 00 | Business Wire | Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/14 | 07 : 15 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/13 | 06 : 52 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/12 | 20 : 01 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/09 | 07 : 31 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/08 | 06 : 13 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/08 | 06 : 05 | Business Wire | NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/07 | 06 : 58 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
| 2024/11/07 | 06 : 46 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NBY | NovaBay Pharmaceuticals Inc New |
